IFC are delighted to have been appointed by Cambridge Cognition to act as their Financial PR and Investor Relations advisers.
Cambridge Cognition (AIM: COG) is a neuroscience digital health company specialising in the precise measurement of clinical outcomes in neurological disorders. The Company develops, and markets validated near patient assessment products using cognition as a biomarker to improve understanding, diagnosis and treatment in brain health worldwide.
IFC will be working with Cambridge Cognition to build its broker, analyst and wider stakeholder followings by increasing its exposure to national dailies and creating a strong brand image and asserting a gripping story.


Dec 2025 – IFC advises on $2.4bn takeover of Alphawave Semi
IFC advises on $2.4bn takeover of Alphawave Semi
Dec
Nov 2025 – IFC advises on £35m Zotefoams acquisition of OKC
IFC advises on £35m Zotefoams acquisition of OKC
Nov
Nov 2025 – Ethtry plc appoints IFC
Ethtry plc appoints IFC
Nov